Ignite Creation Date:
2025-12-24 @ 7:56 PM
Ignite Modification Date:
2026-01-10 @ 3:41 PM
Study NCT ID:
NCT03147404
Status:
COMPLETED
Last Update Posted:
2019-12-30
First Post:
2017-05-08
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic （GEP） Neuroendocrine Carcinoma （NEC, WHO Grade 3） as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes
Sponsor:
Samsung Medical Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-12-28
Start Date Type:
ACTUAL
Primary Completion Date:
2019-07-22
Primary Completion Date Type:
ACTUAL
Completion Date:
2019-07-22
Completion Date Type:
ACTUAL
First Submit Date:
2017-05-08
First Submit QC Date:
None
Study First Post Date:
2017-05-10
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-12-26
Last Update Post Date:
2019-12-30
Last Update Post Date Type:
ACTUAL